my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseas more
Heptares Therapeutics announced that an operating company of Shire plc has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation o more
arGEN-X announced that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire. Using its SIMPLE Antibody™ discovery technology, arGEN-X will isolate and characterize human antibodies against the targets that Shire has iden more
Shire plc announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme® (agalsidase beta) and the long-term safety and benefits of switching to VPRIV (velaglucerase alfa) from Cerezyme® (imiglucerase). Study results are being more
Deal watch: Acceleron and Shire to target the activin receptor pathway for muscular disorders Nature Reviews Drug Discovery 9, 830 (2010). doi:10.1038/nrd3308 Acceleron Pharma and Shire announced in September this year their deal to collaborate on the commercialization and the development o more
Velaglucerase alfa Nature Reviews Drug Discovery 9, 837 (2010). doi:10.1038/nrd3311 Authors: Johannes M. F. G. Aerts, Uma Yasothan & Peter Kirkpatrick In February 2010, velaglucerase alfa (Vpriv; Shire) was approved by the US Food and Drug Administration as a long-term enzyme replacement t more
Habitat fragmentation can act to cause reproductive isolation between conspecifics and undermine species’ persistence, though most studies have reported the genetic condition of populations that have already declined to a very small size. We examined genetic diversity within the vulnerable, declinin more
GBI Research has released its latest research, “Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher’s and Niemann-Pick Poised to Supersede Existing Therapies” which provides insights into global neurometabolic disorders market and market forecast until 2017. R more
Introduction GlobalData, the industry analysis specialist, has released its new report, “Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Gaucher's Disease Therapeutics market. The report more
Introduction GlobalData, the industry analysis specialist, has released its new report, “Hunter Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Hunter Syndrome Therapeutics market. The report iden more
Contact | FAQ | Site Map About – Vision – Management – The Board – Pharmaceutical Partners – Investors – Business Strategy – Corporate Governance – Company FAQ – Contact LNA Drug Platform – Drug Discovery Engine – microRNA – mRNA – Publications Product Pipeline – Drug Candidates Intellectual Pro more
Home Sitemap | Contact Home Therapeutic Areas Portfolio Technology Platform Media About ACE BioSciences Nov 07th 09 - Zymenex acquires ACE Biosciences Zymenex acquires ACE Biosciences Zymenex Holding A/S (Hillerød, Denmark) has today announced that they have acquired all the shares in ACE Bioscience more
Home Impressum About us Management Team Advisory Board Investors Business Markets Partners Technology Discovery Library Generation Assay Development & Screening Confocal Fluorimetry Intellectual Property Applications Protein Engineering Protease Strain Development Developing a Lactic acid strain Pro more
Watchlist
This is where you can add this topic to your personal favourites
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
